Review article: Vitamin D and inflammatory bowel diseases

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 2, 2014, Pages 125-136

  Mouli, V P ^a   Ananthakrishnan, A N ^b,c  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; 7 DEHYDROCHOLESTEROL; ALFACALCIDOL; CALCIFEDIOL; CALCITRIOL; CALCIUM; COLECALCIFEROL; CORTICOSTEROID; ERGOCALCIFEROL; PLACEBO; VITAMIN D; VITAMIN D BINDING PROTEIN; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ADAPTIVE IMMUNITY; ANTIPROLIFERATIVE ACTIVITY; BONE HEALTH; BONE METABOLISM; BONE TURNOVER; CALCIUM DIET; CHOLESTEROL SYNTHESIS; CLINICAL PRACTICE; COLITIS; CROHN DISEASE; DENMARK; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; DIET; DIETARY INTAKE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; EVIDENCE BASED PRACTICE; EXPERIMENTAL MODEL; GASTROINTESTINAL SURGERY; GENE FUNCTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEALTH; HOSPITALIZATION; HUMAN; HYDROXYLATION; IMMUNOPATHOGENESIS; INFLAMMATORY BOWEL DISEASE; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MINERAL METABOLISM; MONOTHERAPY; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIATION EXPOSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SURGICAL RISK; TREATMENT DURATION; TREATMENT OUTCOME; ULCERATIVE COLITIS; ULTRAVIOLET B RADIATION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION;

ANIMALS; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84890560881     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12553     Document Type: Review

References (95)

1. Abraham C, Cho JH,. Inflammatory bowel disease. N Engl J Med 2009; 361: 2066-78.
2. Khor B, Gardet A, Xavier RJ,. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011; 474: 307-17.
3. Jostins L, Ripke S, Weersma RK, et al,. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119-24.
4. Ananthakrishnan AN,. Environmental triggers for inflammatory bowel disease. Curr Gastroenterol Rep 2013; 15: 302.
5. Holick MF,. Vitamin D deficiency. N Engl J Med 2007; 357: 266-81.
6. Holick MF,. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004; 80: 1678S-88S.
7. Rosen CJ,. Clinical practice. Vitamin D insufficiency. N Engl J Med 2011; 364: 248-54.
8. Ananthakrishnan AN, Khalili H, Higuchi LM, et al,. Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. Gastroenterology 2012; 142: 482-9.
9. Cantorna MT, Mahon BD,. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood) 2004; 229: 1136-42.
10. Cantorna MT, Zhu Y, Froicu M, Wittke A,. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 2004; 80: 1717S-20S.
11. Garg M, Lubel JS, Sparrow MP, Holt SG, Gibson PR,. Review article: vitamin D and inflammatory bowel disease-established concepts and future directions. Aliment Pharmacol Ther 2012; 36: 324-44.
12. Jorgensen SP, Agnholt J, Glerup H, et al,. Clinical trial: vitamin D3 treatment in Crohn's disease-a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther 2010; 32: 377-83.
13. Ananthakrishnan AN, Cagan A, Gainer VS, et al,. Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn's disease. Inflamm Bowel Dis 2013; 19: 1921-7.
14. Norman AW,. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr 2008; 88: 491S-9S.
15. Bienaime F, Prie D, Friedlander G, Souberbielle JC,. Vitamin D metabolism and activity in the parathyroid gland. Mol Cell Endocrinol 2011; 347: 30-41.
16. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al,. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911-30.
17. Levin AD, Wadhera V, Leach ST, et al,. Vitamin D deficiency in children with inflammatory bowel disease. Dig Dis Sci 2011; 56: 830-6.
18. Alkhouri RH, Hashmi H, Baker RD, Gelfond D, Baker SS,. Vitamin and mineral status in patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2013; 56: 89-92.
19. Ulitsky A, Ananthakrishnan AN, Naik A, et al,. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. JPEN J Parenter Enteral Nutr 2011; 35: 308-16.
20. Leslie WD, Miller N, Rogala L, Bernstein CN,. Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Am J Gastroenterol 2008; 103: 1451-9.
21. Gilman J, Shanahan F, Cashman KD,. Determinants of vitamin D status in adult Crohn's disease patients, with particular emphasis on supplemental vitamin D use. Eur J Clin Nutr 2006; 60: 889-96.
22. McCarthy D, Duggan P, O'Brien M, et al,. Seasonality of vitamin D status and bone turnover in patients with Crohn's disease. Aliment Pharmacol Ther 2005; 21: 1073-83.
23. Vagianos K, Bector S, McConnell J, Bernstein CN,. Nutrition assessment of patients with inflammatory bowel disease. JPEN J Parenter Enteral Nutr 2007; 31: 311-9.
24. Harries AD, Brown R, Heatley RV, Williams LA, Woodhead S, Rhodes J,. Vitamin D status in Crohn's disease: association with nutrition and disease activity. Gut 1985; 26: 1197-203.
25. Tajika M, Matsuura A, Nakamura T, et al,. Risk factors for vitamin D deficiency in patients with Crohn's disease. J Gastroenterol 2004; 39: 527-33.
26. Leichtmann GA, Bengoa JM, Bolt MJ, Sitrin MD,. Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in patients with both Crohn's disease and intestinal resection. Am J Clin Nutr 1991; 54: 548-52.
27. Sentongo TA, Semaeo EJ, Stettler N, Piccoli DA, Stallings VA, Zemel BS,. Vitamin D status in children, adolescents, and young adults with Crohn disease. Am J Clin Nutr 2002; 76: 1077-81.
28. Vogelsang H, Schofl R, Tillinger W, Ferenci P, Gangl A,. 25-hydroxyvitamin D absorption in patients with Crohn's disease and with pancreatic insufficiency. Wien Klin Wochenschr 1997; 109: 678-82.
29. Farraye FA, Nimitphong H, Stucchi A, et al,. Use of a novel vitamin D bioavailability test demonstrates that vitamin D absorption is decreased in patients with quiescent Crohn's disease. Inflamm Bowel Dis 2011; 17: 2116-21.
30. Wang TJ, Zhang F, Richards JB, et al,. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010; 376: 180-8.
31. Kim S, Shevde NK, Pike JW,. 1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts. J Bone Miner Res 2005; 20: 305-17.
32. McDonnell DP, Pike JW, O'Malley BW,. The vitamin D receptor: a primitive steroid receptor related to thyroid hormone receptor. J Steroid Biochem 1988; 30: 41-6.
33. Cantorna MT, Mahon BD,. D-hormone and the immune system. J Rheumatol Suppl 2005; 76: 11-20.
34. Christakos S,. Recent advances in our understanding of 1,25-dihydroxyvitamin D(3) regulation of intestinal calcium absorption. Arch Biochem Biophys 2011; 523: 73-6.
35. Takeda S, Yoshizawa T, Nagai Y, et al,. Stimulation of osteoclast formation by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells: studies using VDR knockout mice. Endocrinology 1999; 140: 1005-8.
36. Yasuda H, Shima N, Nakagawa N, et al,. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998; 95: 3597-602.
37. Lips P,. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001; 22: 477-501.
38. Ardizzone S, Bollani S, Bettica P, Bevilacqua M, Molteni P, Bianchi Porro G,. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis. J Intern Med 2000; 247: 63-70.
39. Bernstein CN, Leslie WD,. Review article: osteoporosis and inflammatory bowel disease. Aliment Pharmacol Ther 2004; 19: 941-52.
40. Siffledeen JS, Fedorak RN, Siminoski K, et al,. Bones and Crohn's: risk factors associated with low bone mineral density in patients with Crohn's disease. Inflamm Bowel Dis 2004; 10: 220-8.
41. Reffitt DM, Meenan J, Sanderson JD, Jugdaohsingh R, Powell JJ, Thompson RP,. Bone density improves with disease remission in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2003; 15: 1267-73.
42. Kong YY, Feige U, Sarosi I, et al,. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402: 304-9.
43. Redlich K, Hayer S, Ricci R, et al,. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002; 110: 1419-27.
44. Jahnsen J, Falch JA, Mowinckel P, Aadland E,. Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. Scand J Gastroenterol 2002; 37: 192-9.
45. Zehnder D, Bland R, Williams MC, et al,. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 2001; 86: 888-94.
46. Liu PT, Stenger S, Li H, et al,. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311: 1770-3.
47. Liu PT, Schenk M, Walker VP, et al,. Convergence of IL-1beta and VDR activation pathways in human TLR2/1-induced antimicrobial responses. PLoS ONE 2009; 4: e5810.
48. Adams JS, Ren S, Liu PT, et al,. Vitamin D-directed rheostatic regulation of monocyte antibacterial responses. J Immunol 2009; 182: 4289-95.
49. Yuk JM, Shin DM, Lee HM, et al,. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe 2009; 6: 231-43.
50. Wu S, Sun J,. Vitamin D, vitamin D receptor, and macroautophagy in inflammation and infection. Discov Med 2011; 11: 325-35.
51. Wang J, Lian H, Zhao Y, Kauss MA, Spindel S,. Vitamin D3 induces autophagy of human myeloid leukemia cells. J Biol Chem 2008; 283: 25596-605.
52. Sly LM, Lopez M, Nauseef WM, Reiner NE,. 1alpha,25-Dihydroxyvitamin D3-induced monocyte antimycobacterial activity is regulated by phosphatidylinositol 3-kinase and mediated by the NADPH-dependent phagocyte oxidase. J Biol Chem 2001; 276: 35482-93.
53. Liu PT, Modlin RL,. Human macrophage host defense against Mycobacterium tuberculosis. Curr Opin Immunol 2008; 20: 371-6.
54. Liu PT, Stenger S, Tang DH, Modlin RL,. Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol 2007; 179: 2060-3.
55. Arnedo-Pena A, Juan-Cerdan JV, Romeu-Garcia A, et al,. Latent tuberculosis infection, tuberculin skin test and vitamin D status in contacts of tuberculosis patients: a cross-sectional and case-control study. BMC Infect Dis 2011; 11: 349.
56. Ganmaa D, Giovannucci E, Bloom BR, et al,. Tuberculin skin test conversion, and latent tuberculosis in Mongolian school-age children: a randomized, double-blind, placebo-controlled feasibility trial. Am J Clin Nutr 2012; 96: 391-6.
57. Toss G, Symreng T,. Delayed hypersensitivity response and vitamin D deficiency. Int J Vitam Nutr Res 1983; 53: 27-31.
58. Zhang Y, Leung DY, Richers BN, et al,. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol 2012; 188: 2127-35.
59. Brennan A, Katz DR, Nunn JD, et al,. Dendritic cells from human tissues express receptors for the immunoregulatory vitamin D3 metabolite, dihydroxycholecalciferol. Immunology 1987; 61: 457-61.
60. Adorini L, Penna G, Giarratana N, Uskokovic M,. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. J Cell Biochem 2003; 88: 227-33.
61. Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R,. Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci U S A 2001; 98: 6800-5.
62. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC,. 1,25- dihydroxyvitamin D3 receptors in human leukocytes. Science 1983; 221: 1181-3.
63. Lemire JM, Adams JS, Kermani-Arab V, Bakke AC, Sakai R, Jordan SC,. 1,25-Dihydroxyvitamin D3 suppresses human T helper/inducer lymphocyte activity in vitro. J Immunol 1985; 134: 3032-5.
64. Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE,. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 2007; 179: 1634-47.
65. Khalili H, Huang ES, Ananthakrishnan AN, et al,. Geographical variation and incidence of inflammatory bowel disease among US women. Gut 2012; 61: 1686-92.
66. Nerich V, Jantchou P, Boutron-Ruault MC, et al,. Low exposure to sunlight is a risk factor for Crohn's disease. Aliment Pharmacol Ther 2011; 33: 940-5.
67. Kong J, Zhang Z, Musch MW, et al,. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol 2008; 294: G208-16.
68. Dresner-Pollak R, Ackerman Z, Eliakim R, Karban A, Chowers Y, Fidder HH,. The BsmI vitamin D receptor gene polymorphism is associated with ulcerative colitis in Jewish Ashkenazi patients. Genet Test 2004; 8: 417-20.
69. Naderi N, Farnood A, Habibi M, et al,. Association of vitamin D receptor gene polymorphisms in Iranian patients with inflammatory bowel disease. J Gastroenterol Hepatol 2008; 23: 1816-22.
70. Simmons JD, Mullighan C, Welsh KI, Jewell DP,. Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility. Gut 2000; 47: 211-4.
71. Eloranta JJ, Wenger C, Mwinyi J, et al,. Association of a common vitamin D-binding protein polymorphism with inflammatory bowel disease. Pharmacogenet Genomics 2011; 21: 559-64.
72. Cantorna MT, Munsick C, Bemiss C, Mahon BD,. 1,25- Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 2000; 130: 2648-52.
73. Liu N, Nguyen L, Chun RF, et al,. Altered endocrine and autocrine metabolism of vitamin D in a mouse model of gastrointestinal inflammation. Endocrinology 2008; 149: 4799-808.
74. Zhu Y, Mahon BD, Froicu M, Cantorna MT,. Calcium and 1 alpha,25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur J Immunol 2005; 35: 217-24.
75. Daniel C, Sartory NA, Zahn N, Radeke HH, Stein JM,. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther 2008; 324: 23-33.
76. El-Matary W, Sikora S, Spady D,. Bone mineral density, vitamin D, and disease activity in children newly diagnosed with inflammatory bowel disease. Dig Dis Sci 2011; 56: 825-9.
77. Narula N, Marshall JK,. Management of inflammatory bowel disease with vitamin D: beyond bone health. J Crohns Colitis 2012; 6: 397-404.
78. Verlinden L, Leyssens C, Beullens I, et al,. The vitamin D analog TX527 ameliorates disease symptoms in a chemically induced model of inflammatory bowel disease. J Steroid Biochem Mol Biol 2013; 136: 107-11.
79. Zator ZA, Cantu SM, Konijeti GG, et al,. Pre-treatment 25-hydroxy vitamin D levels and durability of anti-tumor necrosis factor α therapy in inflammatory bowel diseases. JPEN J Parenter Enteral Nutr 2013 [Epub ahead of print].
80. Miheller P, Muzes G, Hritz I, et al,. Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. Inflamm Bowel Dis 2009; 15: 1656-62.
81. Yang L, Weaver V, Smith JP, Bingaman S, Hartman TJ, Cantorna MT,. Therapeutic effect of vitamin D supplementation in a pilot study of Crohn's patients. Clin Transl Gastroenterol 2013; 4: e33.
82. Ross AC, Manson JE, Abrams SA, et al,. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011; 96: 53-8.
83. Pappa HM, Mitchell PD, Jiang H, et al,. Treatment of vitamin D insufficiency in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing three regimens. J Clin Endocrinol Metab 2012; 97: 2134-42.
84. Driscoll RH Jr, Meredith SC, Sitrin M, Rosenberg IH,. Vitamin D deficiency and bone disease in patients with Crohn's disease. Gastroenterology 1982; 83: 1252-8.
85. Lamb EJ, Wong T, Smith DJ, et al,. Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 1895-902.
86. Siffledeen JS, Siminoski K, Steinhart H, Greenberg G, Fedorak RN,. The frequency of vitamin D deficiency in adults with Crohn's disease. Can J Gastroenterol 2003; 17: 473-8.
87. Pappa HM, Gordon CM, Saslowsky TM, et al,. Vitamin D status in children and young adults with inflammatory bowel disease. Pediatrics 2006; 118: 1950-61.
88. Kuwabara A, Tanaka K, Tsugawa N, et al,. High prevalence of vitamin K and D deficiency and decreased BMD in inflammatory bowel disease. Osteoporos Int 2009; 20: 935-42.
89. Joseph AJ, George B, Pulimood AB, Seshadri MS, Chacko A,. 25(OH) vitamin D level in Crohn's disease: association with sun exposure & disease activity. Indian J Med Res 2009; 130: 133-7.
90. Pappa HM, Langereis EJ, Grand RJ, Gordon CM,. Prevalence and risk factors for hypovitaminosis D in young patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011; 53: 361-4.
91. Atia A, Murthy R, Bailey BA, et al,. Vitamin D status in veterans with inflammatory bowel disease: relationship to health care costs and services. Mil Med 2011; 176: 711-4.
92. Suibhne TN, Cox G, Healy M, O'Morain C, O'Sullivan M,. Vitamin D deficiency in Crohn's disease: prevalence, risk factors and supplement use in an outpatient setting. J Crohns Colitis 2012; 6: 182-8.
93. Fu YT, Chatur N, Cheong-Lee C, Salh B,. Hypovitaminosis D in adults with inflammatory bowel disease: potential role of ethnicity. Dig Dis Sci 2012; 57: 2144-8.
94. Laakso S, Valta H, Verkasalo M, Toiviainen-Salo S, Viljakainen H, Makitie O,. Impaired bone health in inflammatory bowel disease: a case-control study in 80 pediatric patients. Calcif Tissue Int 2012; 91: 121-30.
95. Hassan V, Hassan S, Seyed-Javad P, et al,. Association between Serum 25 (OH) Vitamin D concentrations and inflammatory bowel diseases (IBDs) activity. Med J Malaysia 2013; 68: 34-8.